APA (7th ed.) Citation

J, B., HM, B., RM, H., J, M., T, S., G, D., . . . K, K. (2025). Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease. The journal of prevention of Alzheimer's disease, 12(7), 100202. https://doi.org/10.1016/j.tjpad.2025.100202

Chicago Style (17th ed.) Citation

J, Burton, Brothers HM, Hutchison RM, Murphy J, Sun T, Dent G, Curiale G, and Kowalski K. "Lower Baseline Amyloid Beta Burden Is Associated with Greater Percent of Amyloid Beta Positron Emission Tomography Reduction and Better Clinical Outcomes in the Aducanumab Phase 3 Trials ENGAGE and EMERGE in Early Alzheimer's Disease." The Journal of Prevention of Alzheimer's Disease 12, no. 7 (2025): 100202. https://doi.org/10.1016/j.tjpad.2025.100202.

MLA (9th ed.) Citation

J, Burton, et al. "Lower Baseline Amyloid Beta Burden Is Associated with Greater Percent of Amyloid Beta Positron Emission Tomography Reduction and Better Clinical Outcomes in the Aducanumab Phase 3 Trials ENGAGE and EMERGE in Early Alzheimer's Disease." The Journal of Prevention of Alzheimer's Disease, vol. 12, no. 7, 2025, p. 100202, https://doi.org/10.1016/j.tjpad.2025.100202.